A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs PT 112 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Phosplatin Therapeutics
- 03 Sep 2019 Planned End Date changed from 30 Jun 2019 to 31 Mar 2020.
- 03 Sep 2019 Planned primary completion date changed from 31 May 2019 to 31 Mar 2020.
- 07 Feb 2018 According to a Phosplatin Therapeutics media release, the company has enrolled the first cohort of patients in this trial.